Search
01/11/2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Wu, YL, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35)DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3.674(Q3/7D).
01/11/2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).
01/11/2021
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers
Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).
01/11/2021
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?
Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Álava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., López Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2021; 32(12)DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51.769(Q1/1D).
01/11/2021
Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4
Serna, N, Carratala, JV, Conchillo-Sole, O, Martinez-Torro, C, Unzueta, U, Mangues, R, Ferrer-Miralles, N, Daura, X, Vazquez, E, Villaverde, A. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics. 2021; 13(11)DOI:10.3390/pharmaceutics13111922. PMID:34834337. IF:6.525(Q1/2D).
01/11/2021
Anatomic mapping of the collateral branches of the external carotid artery with regard to daily clinical practice
Cobiella, R, Quinones, S, Aragones, P, Leon, X, Abramovic, A, Vazquez, T, Sanudo, JR, Maranillo, E, Olewnik, L, de Blas, CS, Parkin, I, Konschake, M. Anatomic mapping of the collateral branches of the external carotid artery with regard to daily clinical practice. ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER. 2021; 238DOI:10.1016/j.aanat.2021.151789. PMID:34214605. IF:2.976(Q1/2D).
01/11/2021
Salvage carbon dioxide transoral laser microsurgery for laryngeal cancer after (chemo)radiotherapy: a European Laryngological Society consensus statement
Piazza, C, Paderno, A, Sjogren, EV, Bradley, PJ, Eckel, HE, Makitie, A, Matar, N, Paleri, V, Peretti, G, Puxeddu, R, Quer, M, Remacle, M, Vander Poorten, V, Vilaseca, I, Simo, R. Salvage carbon dioxide transoral laser microsurgery for laryngeal cancer after (chemo)radiotherapy: a European Laryngological Society consensus statement. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2021; 278(11)DOI:10.1007/s00405-021-06957-5. PMID:34226992. IF:3.236(Q2/3D).
01/11/2021
Differential characteristics of patients with squamous cell carcinoma of the head and neck according to gender
Leon, X, Garcia, J, Lopez, M, Holgado, A, Llansana, A, Quer, M. Differential characteristics of patients with squamous cell carcinoma of the head and neck according to gender. Acta Otorrinolaringologica Espanola. 2021; 72(6)DOI:10.1016/j.otorri.2020.08.009. PMID:33618830. IF:(Q/D).